TWSTTwist Bioscience Corporation
Price
+473%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis.
In the company’s own words · 10-K filed Nov 17, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Twist Bioscience Corporation (TWST) reported revenue of $118M in Q3 2026 (quarter ended Jun 30, 2026), up 23% from the same quarter a year earlier. That came with a gross margin of 53% and net loss of $35M. For the full year FY2025, revenue was $377M (+20% year on year) and net income −$78M. Its largest product in Q3 2026 was Ngs Tools at $62M, 52% of the disclosed total, just ahead of Antibody Discovery at 48%. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026Pursuant to that certain Registration Rights Agreement dated February 11, 2026 by and between Twist Bioscience Corporation (the “Company”) and Invenra Inc. (“Invenra”), the Company is filing a prospectus supplement to register the resale of shares issuable pursuant to that certain Stock Purchase Agreement dated …Other event · Form 8-K
- Aug 5, 2026On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein …Material agreement entered · Form 8-K
- Aug 3, 2026Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2026 · $118.4MThe company’s own SEC segment disclosure.
- Ngs Tools$61.8M52%
- Antibody Discovery$56.6M48%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #20 of 21 by RyuScore